Commentary
Effective but inaccessible antiobesity medications: A call for sharing responsibility for improving access to evidence-based care
Bartolome Burguera, MD, PhD, Marcio L. Griebeler, MD and W. Timothy Garvey, MD
Cleveland Clinic Journal of Medicine November 2024, 91 (11) 671-676; DOI: https://doi.org/10.3949/ccjm.91a.24068
Bartolome Burguera
Chief, Medical Specialty Institute, Cleveland Clinic, Cleveland, OH; Chair, Department of Endocrinology and Metabolism, Cleveland Clinic, Cleveland, OH; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Marcio L. Griebeler
Department of Endocrinology and Metabolism, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
W. Timothy Garvey
Associate Director, Department of Nutrition Sciences and the University of Alabama at Birmingham Diabetes Research Center, University of Alabama at Birmingham, Birmingham AL; Professor, University of Alabama at Birmingham, Birmingham AL

Article Figures & Data
Tables
- TABLE 1
US list prices (monthly cost) of second-generation antiobesity medications compared with selected other countries
United States Spain Denmark Netherlands United Kingdom Japan Canada Dubai Semaglutide 2.4 mg $1,349 $314 $343 $296 $233 $69 $388 $326 Tirzepatide 10–15 mg $1,069 $400 $632 $444 $162 $319 $104 $472 Information based on web searches, direct pharmacy pricing information, and reference 22.
In this issue
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 11
1 Nov 2024
Effective but inaccessible antiobesity medications: A call for sharing responsibility for improving access to evidence-based care
Bartolome Burguera, Marcio L. Griebeler, W. Timothy Garvey
Cleveland Clinic Journal of Medicine Nov 2024, 91 (11) 671-676; DOI: 10.3949/ccjm.91a.24068
Jump to section
Related Articles
- No related articles found.